drug pricing

The Readout Meghana Keshavan

STAT Plus: What makes a drug a blockbuster — or a cautionary tale?

The Readout Damian Garde

Novavax is on thin ice, and the latest update isn’t exactly encouraging

The Readout Damian Garde

STAT Plus: Pfizer’s reset year starts with a little profit

The Readout Damian Garde

STAT Plus: How an immunological Trojan horse could treat disease

The Readout Meghana Keshavan

STAT Plus: 23andMe breach targeted Chinese, Jewish populations

The Readout Damian Garde

STAT Plus: Eli Lilly overtakes Tesla in market value

The Readout Damian Garde

STAT Plus: Another step toward new drugs for Parkinson’s

The Readout Meghana Keshavan

STAT Plus: Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment

The Readout Meghana Keshavan

STAT Plus: Investigators fault Lilly plant for manufacturing issues

The Readout Meghana Keshavan

The Senate health committee looks into its first subpoena in 40 years

The Readout Damian Garde

STAT Plus: The XBI comedown after JPM

The Readout Damian Garde

STAT Plus: The big any-day-now biotech news we’re keeping an eye on

The Readout Meghana Keshavan

STAT Plus: The four biotech stories you need to read this morning

The Readout Meghana Keshavan

STAT Plus: Novartis reportedly decides to pass on Cytokinetics

The Readout Damian Garde, Allison DeAngelis, Adam Feuerstein, and Matthew Herper

STAT Plus: The highs — and lows — of JPM 2024 you should pay attention to

The Readout Damian Garde, Adam Feuerstein, Matthew Herper, and Allison DeAngelis

STAT Plus: JPM Day 3 had a cautiously optimistic outlook

The Readout Damian Garde, Adam Feuerstein, Matthew Herper, and Allison DeAngelis

STAT Plus: JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far

Adam Feuerstein, Allison DeAngelis, Damian Garde, and Matthew Herper

STAT Plus: This is the TLDR of JPM Day 1

The Readout Damian Garde

STAT Plus: Why CG Oncology will be the first test of 2024’s IPO waters

The Readout Damian Garde

STAT Plus: Anavex’s slow journey to failure

Pharmalot Ed Silverman

STAT Plus: 3 issues to watch in pharma in 2024

Morning Rounds Elizabeth Cooney

Morning Rounds: Our newsroom’s favorite stories of 2023

The Readout Damian Garde

STAT Plus: The clock is ticking, and Cytokinetics is running out of December

The Readout Damian Garde

STAT Plus: BioMarin appeases an activist

The Readout Meghana Keshavan

Inhaled vaccines could stop Covid infections, monkey studies show

The Readout Meghana Keshavan

STAT Plus: The biotech updates you need to read today

The Readout Meghana Keshavan

STAT Plus: The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive

The Readout Meghana Keshavan

STAT Plus: FDA chastens pet companies over antibiotics

The Readout Damian Garde

STAT Plus: Is it time to worry about Moderna?